Physician profile
Adnan S Peer
NPI 1962693150
$49,313.66
in general payments reported to CMS, 2019-2025
47 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,260 · 2021: $3,068 · 2022: $3,899 · 2023: $10K · 2024: $4,389 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $11K · Travel and Lodging: $2,414 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,455.40 |
| Consulting Fee | $11,009.38 |
| Travel and Lodging | $2,413.51 |
| Education | $188.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,604.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $5,421.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $5,194.39 | 2019-2025 | Benlysta |
| Amgen INC. | $4,768.25 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Horizon Therapeutics Plc | $4,055.82 | 2019-2023 | Krystexxa |
| Ucb, INC. | $2,973.07 | 2019-2025 | Cimzia, Bimzelx, Neupro |
| Janssen Biotech, INC. | $1,962.52 | 2019-2025 | Tremfya, Simponi Aria |
| Celgene Corporation | $1,813.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,546.42 | 2021-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $1,249.00 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $1,210.80 | 2020-2025 | Acthar |
| Pfizer INC. | $1,173.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,106.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $614.57 | 2019-2025 | Orencia, Sotyktu |
| Radius Health, INC. | $555.09 | 2019-2025 | Tymlos |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Peer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.